DNMT3A and acute myeloid leukemia: On the other hand, AML patients with the DNMT3A mutations and NPM1 mutations presented significantly lower expression of TRH (p = 0.0035 and p < 0.001, respectively) compared with the corresponding wild-type groups (Figure 3c).